ObjectiveTo explore the clinical effects of continuous renal replacement therapy combined with ulinastatin in the treatment of patients with severe acute pancreatitis. MethodA total of 116 patients with severe acute pancreatitis who were admitted to our hospital from March 2018 to October 2020 were selected as the research objects, and they were divided into observation group and control group according to the order of visits, with 58 cases in each group. The control group was given conventional treatment, whereas the observation group was given continuous renal replacement therapy combined with ulinastatin. The course of treatment was 28 days. The clinical efficacy, pre- and post-treatment APACHE II scores, Balthazar CT scores and inflammatory indexes levels were compared between the two groups. The time for abdominal pain relief, for blood amylase and urine amylase levels returned to normal, and for staying in ICU for treatment were compared between the two groups. ResultsAfter 28 days of treatment, the clinical efficacy of the observation group was significantly superior to that of the control group (P＜0.05). After treatment, the levels of IL-6, CRP, PCT, and the scores of APACHE II and Balthazar CT in both groups significantly decreased, and the levels and scores of the observation group were significantly lower than those of the control group, with statistically significant differences (P＜0.05). The time for abdominal pain relief, for blood amylase and urine amylase levels returned to normal, for staying in ICU for treatment in the observation group were significantly shorter than those in the control group, with statistically significant differences (P＜0.05). ConclusionContinuous renal replacement therapy combined with ulinastatin has significant clinical efficacy in the treatment of patients with severe acute pancreatitis, which can effectively reduce the inflammatory response in patients, promote recovery, and improve prognosis.

无